Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Knowledge Hub

Pneumococcal disease vaccines significantly reduced cases within the first years of use

Data obtained through active surveillance pre and post introduction of PCV in the US showed that the vaccine averted an estimated 38,000 cases of invasive pneumococcal disease within its first five years of use. Additionally, 71,000 cases of disease were estimated to be prevented by herd effects.

Full Citation:
Ray, G.T., Whitney, C., Fireman, B., et al. 2006. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatric Infectious Disease Journal. 25(6).

Title of Article: Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

Author(s): Ray, G.T., Whitney, C., Fireman, B., et al

Publication Year: 2006

Publication Name: Pediatric Infectious Disease Journal

Publication Volume: 25(6)

Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/16732146/

DOI (Digital Object Identifier): 10.1097/01.inf.0000222403.42974.8b

Topics: Health

Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia

Countries: United States

WHO Regions: Americas